Quench Bio is a biotechnology company leveraging new insights into gasdermin biology and innate immunity to develop medicines for severe inflammatory diseases. Quench's lead compounds target and inhibit the pore-forming protein Gasdermin D, a central player in both pyroptosis and NETosis pathways that mediates the release of inflammatory cytokines, alarmins, DNA and NETs. Quench Bio launched in January 2020 with $50 million from leading life science investors including Atlas Venture, Arix Bioscience, RA Capital and AbbVie Ventures.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/27/20 | $50,000,000 | Series A |
AbbVie Biotech Ventures Arix Bioscience Atlas Venture RA Capital Management  | undisclosed |
